A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

J. Reckweg*, N. Mason, C. Van Leeuwen, S. Tonnes, T. Terwey, J. Ramaekers

*Corresponding author for this work

Research output: Contribution to journalConference Abstract/Poster in journalAcademic

Original languageEnglish
Pages (from-to)S716-S716
Number of pages1
JournalEuropean Psychiatry
Publication statusPublished - 1 Jun 2022


  • GH001
  • 5-MeO-DMT
  • Phase 1
  • Safety

Cite this